Aureon TherapeuticsGet in Touch
AUREON THERAPEUTICS

Precision Drug Delivery.
On Demand.

Advancing lipid nanoparticle technologies for externally triggered drug release, with the goal of improving the precision and effectiveness of cancer therapeutics.

Explore Our Technology
Schematic illustration of a lipid nanoparticle
THE CHALLENGE

Rethinking Drug Delivery

Conventional chemotherapy exposes healthy tissues to potent drugs. Aureon's approach aims to improve spatial control over drug release by combining lipid nanoparticle delivery with externally applied triggers.

Conventional chemotherapy distributing drug throughout tumour and healthy tissues

Conventional Delivery

Systemic drug distribution can expose healthy tissues to chemotherapy, contributing to unwanted toxic side effects.

Lipid nanoparticles releasing chemotherapy near a tumour following laser stimulation

Triggered Delivery

Externally triggered release offers the potential to concentrate drug activity at the target site while limiting off-target exposure.

OUR TECHNOLOGY

Precision Through Controlled Release

Engineered lipid nanoparticles combine therapeutic delivery with externally controlled release.

Encapsulate technology illustration

Encapsulate

Therapeutic agents and responsive gold nanoparticles are co-encapsulated within engineered lipid nanoparticles.

Trigger technology illustration

Trigger

Externally applied energy, such as pulsed laser or X-ray irradiation, activates circulating lipid nanoparticles at the targeted site.

Release technology illustration

Release

The therapeutic cargo is released locally, enabling precise spatial and temporal control over drug delivery.

OUR PEOPLE

Meet the Team

Aureon Therapeutics was founded by researchers with expertise in nanomedicine, lipid nanoparticles, and drug delivery at the University of British Columbia.

Portrait of Yao Zhang

Yao Zhang

Chief Executive Officer and Co-Founder

Lipid nanoparticle formulation, therapeutic cargo loading optimization, and business development.

Portrait of Arash Momeni

Arash Momeni

Chief Scientific Officer and Co-Founder

Nanoparticle synthesis, surface functionalization, and materials engineering.

Portrait of Harrison Fan

Harrison Fan

Chief Technical Officer and Co-Founder

Triggering apparatus development, experimental design, and release characterization.

Portrait of Pieter R. Cullis

Pieter R. Cullis

Co-Founder

Pioneer in lipid nanoparticle technology, nanomedicine, and drug delivery.

GET IN TOUCH

Let's Advance Drug Delivery.

We welcome inquiries about scientific collaborations, pharmaceutical partnerships, and business development opportunities.

Contact Aureon Therapeutics